title: TLR4 signaling promotes a COX-2/PGE2/STAT3 positive feedback loop in hepatocellular carcinoma (HCC) cells.
abstract: Toll-like receptors (TLRs) can be expressed by tumor cells, and each TLR exhibits different biological functions. Evidences showed the activation of some certain TLRs could promote tumor progression. One of which TLR4 has been found to promote hepatocellular carcinoma (HCC) cells proliferation, but the detailed mechanism is still unknown. In the present study, we verified that TLR4 was functionally expressed on HCC cells, and TLR4 agonist lipopolysaccharide (LPS) could stimulate the proliferation and clone formation of HCC cells. Most importantly, we found a COX-2/PGE2/STAT3 positive feedback loop exists in HCC cells, which could be provoked by TLR4 activation. Consistently, the expression of TLR4, COX-2 and p-STAT3Y705was positively correlated with each other in liver tumor tissues from patients with primary HCC. Further investigation demonstrated this loop played a dominant role in TLR4-induced HCC cell proliferation and multidrug resistance (MDR) to chemotherapy. Inhibition of TLR4 or COX-2/PGE2/STAT3 loop would attenuate LPS-induced inflammation and proliferation of HCC cells, and enhance the sensitivity of HCC cells to chemotherapeutics in vitro. By using a primary HCC model, we observed COX-2/PGE2/STAT3 loop was significantly blocked in TLR4-/-mice compared to wild type mice, and there was no obvious tumorgenesis sign in TLR4-/-mice. Therefore, these findings provided the precise molecular mechanism of TLR4 signaling pathway involved in HCC progress, and suggested that TLR4 may be a promising target for HCC treatment.
authors.affiliation: Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Shandong University , Jinan, China.
authors.forename: Ang
authors.initials: A
authors.lastname: Lin
authors.affiliation: Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Shandong University , Jinan, China.
authors.forename: Guan
authors.initials: G
authors.lastname: Wang
authors.affiliation: Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Shandong University , Jinan, China.
authors.forename: Huajun
authors.initials: H
authors.lastname: Zhao
authors.affiliation: Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Shandong University , Jinan, China.
authors.forename: Yuyi
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Shandong University , Jinan, China.
authors.forename: Qiuju
authors.initials: Q
authors.lastname: Han
authors.affiliation: Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Shandong University , Jinan, China.
authors.forename: Cai
authors.initials: C
authors.lastname: Zhang
authors.affiliation: Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Shandong University, Jinan, China; School of Life Sciences, University of Science and Technology of China, Hefei, China.
authors.forename: Zhigang
authors.initials: Z
authors.lastname: Tian
authors.affiliation: Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Shandong University , Jinan, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Zhang
keywords: HCC; STAT3; TLR4; multidrug resistance; proliferation